Immunotherapeutic potential of PD-1 blockade in chronic Leishmania mexicana infection through the enhancement of progenitor-like CXCR5+ and intermediate CXCR5+TIM-3+ exhausted T cells - Takeaways - MDSpire

Immunotherapeutic potential of PD-1 blockade in chronic Leishmania mexicana infection through the enhancement of progenitor-like CXCR5+ and intermediate CXCR5+TIM-3+ exhausted T cells

  • By

  • Mariana Diupotex

  • Julián A. Gajón

  • Laura C. Bonifaz

  • Jaime Zamora-Chimal

  • Ingeborg Becker

  • June 29, 2026

  • 0 min

Share

  • 1

    Diffuse cutaneous leishmaniasis (DCL) caused by Leishmania mexicana is characterized by treatment resistance and high parasite load.

  • 2

    Anti-PD-1 immunotherapy limited lesion progression and reduced parasite burden in chronically infected mice.

  • 3

    Treatment enhanced antigen-specific Th1 immune response and reinvigorated CD8+ and CD4+ T cells in draining lymph nodes.

  • 4

    PD-1 blockade increased progenitor-like and intermediate exhausted T cell populations within lesion sites.

  • 5

    The study suggests PD-1/PD-L1 checkpoint blockade may be a potential immunotherapeutic strategy for DCL.

Original Source(s)

Immunotherapeutic potential of PD-1 blockade in chronic Leishmania mexicana infection through the enhancement of progenitor-like CXCR5+ and intermediate CXCR5+TIM-3+ exhausted T cells

  • by Mariana Diupotex, Julián A. Gajón, Laura C. Bonifaz, Jaime Zamora-Chimal, Ingeborg Becker

  • June 29, 2026

Related Content

Commentary: Impact of systemic immune-inflammation index and systemic inflammation response index on all-cause and cause-specific mortality: a community-based cohort study

Treatment of congenital toxoplasmosis with pyrimethamine combined with sulfadiazine in a Chinese neonate: a case report

Neutrophil EMR3 dynamics in critically ill patients with sepsis: an ICU experience